



CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR 1.10)

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By: Lewis J. Kreisler  
Lewis J. Kreisler

Date: 9-27-05

---

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor(s):	Atkins, et al.	Atty. Ref.:	18013-C1
Appl. No.:	10/717,101	Group Art Unit:	1648
Filed:	November 19, 2003	Examiner:	Bao Q. Li
Conf. No.:	7313	Customer No.:	31976
For:	ONCOLYTIC VIRUS		

\* \* \* \* \*

September 27, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


**INFORMATION DISCLOSURE STATEMENT**

At the request of the Examiner (September 21, 2005 telephone conference), Applicant respectfully submits a Form PTO-1449 listing the journal articles cited in the August 1, 2005 Amendment. Because the journal articles were already submitted with the August 1, 2005 Amendment Examiner Li informed the undersigned that copies do not need to be resubmitted.


Inventor(s): Atkins, et al.  
Application No.: 10/717,101  
Page 2

It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,

  
Lewis J. Kreisler  
Lewis J. Kreisler  
Reg. No. 38522  
Attorney for Applicant(s)

930 Clopper Road  
Gaithersburg, MD 20878  
Phone: (240) 631-2500 x3276  
Facsimile: (240) 683-3794



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number	10/717,101
Filing Date	July 29, 2005
First Named Inventor	Harold L. Atkins
Art Unit	1648
Examiner Name	Bao Q. Li
Attorney Docket Number	18013-C1

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Stojdl, et al., "VSV Strains with Defect in their Ability to Shutdown Innate Immunity are Potent Systemic Anti-Cancer Agents", Cancer Cell, (2003) Vol. 4, pages 263-275.	
		Fernandez, et al., "Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease", Journal of Virology, (2002), Vol. 76, No. 2, pages 295-904.	
		Ebert, et al., "Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-Competent Rats", Cancer Research, (2003), Vol. 63, pages 3605-3611.	
		Ebert, et al., "Systemic Therapy of Experimental Breast Cancer Metastases by Mutant Vesicular Stomatitis Virus in Immune-Competent Mice, Cancer Gene Therapy", (2005), Vol. 12, pages 350-358.	
		Porosnicu, et al., "The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene", Cancer Research, (2003), Vol. 63, pages 8366-8376.	
		Ahmed, et al., "Sensitivity of Prostate Tumors to Wild Type and M Protein Mutant Vesicular Stomatitis Viruses", Virology, (2004), Vol. 330, pages 34-49.	
		Balachandran, et al., "Oncolytic Activity of Vesicular Stomatitis Virus is Effective Against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis", Journal of Virology, (2001), Vol. 75, No. 7, pages 3474-3479.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.